Article Details

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti ... - Benzinga

Retrieved on: 2022-09-27 19:44:02

Tags for this article:

Click the tags to see associated articles and topics

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti ... - Benzinga. View article details on hiswai:

Excerpt

The Company's proprietary antibody technology platforms Harbour Mice ® generate fully human monoclonal antibodies in two heavy and two light chains ( ...

Article found on: www.benzinga.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up